Form 8-K Sarepta Therapeutics, For: Oct 03

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Form 8-K Sarepta Therapeutics, For: Oct 03

Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'

October 4, 2016 9:13 AM EDT

Baird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).

Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More